What is AvantGen?
Founded in 2006 and based in San Diego, AvantGen operates with distinct Therapeutic and Research & Diagnostic divisions. The company specializes in novel human antibody discovery, humanization, and optimization for therapeutic development. AvantGen leverages a proprietary yeast display system, an extensive natural human antibody database, and Germliner fully human antibody libraries, alongside advanced screening technologies. It collaborates with pharmaceutical and biotechnology partners to accelerate antibody-based therapeutic advancements through services, strategic partnerships, and licensing agreements.
How much funding has AvantGen raised?
AvantGen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in AvantGen
PPP
Public-Private Partnership
What's next for AvantGen?
The substantial capital infusion, particularly the recent strategic investment, positions AvantGen for significant scaling and expansion. This late-stage funding context suggests a focus on advancing its therapeutic pipeline towards clinical trials and potentially commercialization. The company is likely to enhance its research and diagnostic capabilities, further solidify its market position in antibody discovery, and explore new strategic alliances to maximize the impact of its proprietary technologies. Future growth will likely involve expanding its operational capacity and potentially pursuing further rounds of financing to support long-term development goals.
See full AvantGen company page
